Mediastinal Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Mediastinal Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy [Phase 2]
Phase 2 trial evaluating frontline immunochemotherapy for primary mediastinal large B-cell lymphoma using antibody therapy combined with a c…
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma [Phase 1]
A Phase 1 exploratory study evaluated CD19-targeted CAR T cells (BZ019) in relapsed/refractory B-cell lymphomas, including diffuse large B-c…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: Intergroup Trial for Children or Adolescents With Primary Mediastinal Large B-Cell Lymphoma: DA-EPOCH-Rituximab Evaluation [Phase 2]
Phase 2 intergroup trial evaluating DA-EPOCH-R with Rituximab in children and adolescents with primary mediastinal large B-cell lymphoma has…
-
CLINICAL_TRIALS trial_result · 2026-02-09Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) [Phase 2]
Phase 2 study evaluating pembrolizumab coformulated with berahyaluronidase alfa (MK-3475A) in relapsed or refractory classical Hodgkin lymph…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma [Phase 2]
Ongoing Phase 2 trial evaluating nivolumab in combination with DA-REPOCH chemotherapy for aggressive B-cell non-Hodgkin lymphomas, including…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update describes testing additional drug treatments after CAR T-cell therapy in patients with relapsed or refractor…
-
CLINICAL_TRIALS trial_result · 2026-01-29Clinical Trial Update: Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas [Phase 2]
Phase 2 study evaluating acalabrutinib plus lisocabtagene maraleucel (Liso-Cel) in refractory/relapsed aggressive B-cell lymphomas, includin…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy [Phase 2]
A Phase 2 trial is evaluating whether vaccination with Prevnar 13 before and after CAR-T therapy can enhance cellular and humoral immunity i…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy [Phase 2]
A Phase 2 clinical trial investigates golcadomide in combination with rituximab as bridging therapy for relapsed or refractory aggressive B-…
-
CLINICAL_TRIALS research · 2026-01-15Clinical Trial Update: Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma [NA]
A Phase III randomized trial is evaluating the role of involved mediastinal radiotherapy after Rituximab-containing chemotherapy in newly di…
-
CLINICAL_TRIALS research · 2026-01-14Clinical Trial Update: Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 1]
This is a Phase 1 trial evaluating anti-CD19 CAR-T cell therapy for relapsed or refractory non-Hodgkin lymphoma. The study is currently recr…
-
CLINICAL_TRIALS trial_result · 2026-01-13Clinical Trial Update: Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial assessing pembrolizumab with external beam radiation therapy in relapsed or refractory non-Hodgkin lymphoma; the study (NCT032…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors [NA]
A clinical trial update describing a study on implementing lifestyle-based survivorship care plans for lymphoma survivors.
-
CLINICAL_TRIALS trial_result · 2025-12-24Clinical Trial Update: Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
A multicenter retrospective study on primary mediastinal large B-cell lymphoma (PMBCL) has been completed, reporting observational findings …
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study of GF-CART01, a CD20/CD19 CAR T cell therapy, evaluating safety and early activity in a…
-
CLINICAL_TRIALS research · 2025-12-18Clinical Trial Update: Long-term Study to Evaluate Safety and Persistence of GF-CART01
This clinical trial update describes a long-term safety and persistence study of GF-CART01, with enrollment not yet starting.
-
CLINICAL_TRIALS trial_result · 2025-12-09Clinical Trial Update: Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T) [NA]
Clinical trial update on adaptive bridging radiotherapy for relapsed/refractory B-cell lymphomas prior to CAR-T therapy; the study status is…
-
CLINICAL_TRIALS research · 2025-11-20Clinical Trial Update: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma [Phase 2]
Phase 2 clinical trial update evaluating Tafasitamab and Lenalidomide followed by Tafasitamab and ICE as salvage therapy for transplant-elig…
-
CLINICAL_TRIALS research · 2025-11-14Clinical Trial Update: Emapalumab Prevention of CAR-T Cell Associated Toxicities [Phase 2]
A Phase 2 clinical trial update evaluating emapalumab for preventing CAR-T cell–related toxicities in patients with relapsed or refractory B…
-
CLINICAL_TRIALS research · 2025-11-06Clinical Trial Update: Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
Phase 1 clinical trial evaluating the combination of Rituximab and Tafasitamab with allogeneic NK cells in relapsed/refractory B-cell non-Ho…
-
CLINICAL_TRIALS trial_result · 2025-10-14Clinical Trial Update: Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies [EARLY_Phase 1]
The document summarizes a Phase 1 trial of dose-adjusted EPOCH-R for mature B-cell malignancies, including Diffuse Large B-Cell Lymphoma, Po…
-
CLINICAL_TRIALS research · 2025-10-09Clinical Trial Update: Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers [NA]
Memorial Sloan Kettering Cancer Center reports an ongoing trial evaluating a communication training intervention for clinicians treating lar…
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial is evaluating the combination of acalabrutinib with anti-CD19 CAR T-cell therapy for various B-cell lymphomas, in…
-
CLINICAL_TRIALS other · 2025-10-06Clinical Trial Update: Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]
A Phase 2 clinical trial is evaluating the combination of loncastuximab tesirine and mosunetuzumab for relapsed or refractory diffuse large …
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…